We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Awareness Technology, Inc.

Awareness Technology, Inc. provides clinical laboratory instrumentation, reagents and assays for small-to-medium-volu... read more Featured Products: More products

Download Mobile App




Awareness Technology Announces ChemWell RPR Analyzer - The Most Significant Innovation in Syphilis Testing in Last 30 Years

By LabMedica International staff writers
Posted on 17 Jul 2020
Awareness Technology, Inc. More...
(Palm City, FL, USA) has announced the most significant innovation in syphilis testing in the last 30 years with the launch of the ChemWell RPR automated nontreponemal analyzer for the detection of syphilis.

Awareness is an international IVD company that develops, manufactures, and markets high quality in-vitro diagnostic instrumentation, and diagnostic test kits. The company’s instrument portfolio includes biochemistry, ELISA, chemiluminescence, imaging analytics, electrolyte instruments, and supportive equipment. Awareness’ diagnostic test kit portfolio includes ELISA kits with a focus on autoimmune and infectious disease testing, biochemistry test kits, and allergy screening kits, which support over 200 specific allergens.

Laboratories can now automate nontreponemal testing and drive significant operational efficiencies while minimizing false-positive results with Awareness’ ChemWell RPR automated nontreponemal analyzer for the detection of syphilis. Designed to work with carbon antigen, the RPR analyzer uses four standard 48 well microwell plates instead of manual RPR cards to analyze up to 192 samples per hour without any user intervention. It utilizes a high resolution imaging system which captures the reaction taking place in each of the back-lit wells that are interpreted by a proven algorithm and provide an accurate and reliable negative or positive result based on the captured images. It can perform visual identification of positive or negative reaction with a sensitivity of 98.8% and a specificity of 99.8%.

An additional test can be run on positive samples to determine titers up to 1:2048 dilution for therapeutic monitoring. The software is included with the user-friendly system at no additional cost and features an intuitive interface that allows for easy navigation and use. Automated features such as fluid handling, mixing, timing, image capture, image processing, and reporting are all handled by the software.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Electrolyte Analyzer
BKE-B
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.